Prevalence of tumour-infiltrating CD103+ cells identifies therapeutic-sensitive prostate cancer with poor clinical outcome

BackgroundThe clinical significance and immune correlation of CD103(+) cells in prostate cancer (PCa) remain explored.MethodsIn total, 1080 patients with PCa underwent radical prostatectomy from three cohorts were enrolled for retrospective analysis. Tumour microarrays were constructed and fresh tumour samples were analysed by flow cytometry.ResultsHigh CD103(+) cell infiltration correlated with reduced biochemical recurrence (BCR)-free survival in PCa. Adjuvant hormone therapy (HT) prolonged the BCR-free survival for high-risk node-negative diseases with CD103(+) cell abundance. CD103(+) cell infiltration correlated with less cytotoxic expression and increased infiltration of CD8(+) and CD4(+) T cells, M1 macrophages and mast cells in PCa. Intratumoral CD8(+) T cell was the predominant source of CD103, and the CD103(+) subset of CD8(+) T cells was featured with high IL-10, PD-1 and CTLA-4 expression. Tumour-infiltrating CD103(+) CD8(+) T cells exerted anti-tumour function when treated with HT ex vivo.DiscussionCD103(+) cell infiltration predicted BCR-free survival and response to adjuvant HT in PCa. CD103(+) cell infiltration correlated with an enriched but immune-evasive immune landscape. The study supported a model that CD103 expression conferred negative prognostic impact and immunosuppressive function to tumour-infiltrating CD8(+) T cells, while the CD103(+) CD8(+) T cells exhibited a powerful anti-tumour immunity with response to HT.

Automated summary

The clinical significance and immune correlation of CD103(+) cells in prostate cancer (PCa) have not been explored. This study found that high CD103(+) cell infiltration was associated with reduced biochemical recurrence (BCR)-free survival in PCa. Adjuvant hormone therapy (HT) prolonged the BCR-free survival in high-risk node-negative cases with abundant CD103(+) cells.